Ruxolitinib Phosphate (CAS 1092939-17-7)
See product citations (1)
QUICK LINKS
Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib (sc-364729). Mouse models have shown it to be a potent and selective Janus kinase (JAK1, IC50 = 5.9 nM and JAK2, IC50 = 5.7 nM) inhibitor. Ruxolitinib has also been shown to suppress interleukin-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM). Ruxolitinib significantly reduced splenomegaly and circulating levels of inflammatory cytokines and selectively eliminated neoplastic cells in mouse models of JAK2V617F+ myeloproliferative neoplasm, prolonging their survival without myelosuppressive or immunosuppressive effects.Further studies of Ruxolitinib have demonstrated its ability to inhibit phosphorylated signal transducer and activator of transcription 3 (STAT3).
Ruxolitinib Phosphate (CAS 1092939-17-7) References
- Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. | Vaddi, K., et al. 2012. Expert Opin Pharmacother. 13: 2397-407. PMID: 23051187
- Ruxolitinib for the treatment of primary myelofibrosis. | Swaim, SJ. 2014. Am J Health Syst Pharm. 71: 453-62. PMID: 24589536
- Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. | Tavallai, M., et al. 2016. Oncotarget. 7: 17290-300. PMID: 26981780
- Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). | Gnanasakthy, A., et al. 2016. J Clin Oncol. 34: 1928-34. PMID: 27069082
- Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. | Tavallai, M., et al. 2016. Front Oncol. 6: 142. PMID: 27379204
- Advances in treating psoriasis in the elderly with small molecule inhibitors. | Cline, A., et al. 2017. Expert Opin Pharmacother. 18: 1965-1973. PMID: 29171774
- Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. | Senkevitch, E., et al. 2018. Oncotarget. 9: 22605-22617. PMID: 29854301
- Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury. | Alexander, KA., et al. 2019. Front Immunol. 10: 377. PMID: 30899259
- Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. | Abedin, SM. and Hamadani, M. 2020. Expert Opin Investig Drugs. 29: 423-427. PMID: 32293938
- Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. | Abedin, S. and Hamadani, M. 2020. J Exp Pharmacol. 12: 549-557. PMID: 33273867
- Ruxolitinib photodegradation mechanisms by theoretical and experimental chemistry. | Secretan, PH., et al. 2021. J Pharm Biomed Anal. 197: 113983. PMID: 33640689
- Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. | Gong, X., et al. 2021. Am J Clin Dermatol. 22: 555-566. PMID: 33982267
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. | Smith, P., et al. 2021. Pharmaceutics. 13: PMID: 34371735
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ruxolitinib Phosphate, 5 mg | sc-396768 | 5 mg | $116.00 | |||
Ruxolitinib Phosphate, 10 mg | sc-396768A | 10 mg | $181.00 | |||
Ruxolitinib Phosphate, 50 mg | sc-396768B | 50 mg | $310.00 | |||
Ruxolitinib Phosphate, 100 mg | sc-396768C | 100 mg | $486.00 |